SCHEMBL3435302

SCHEMBL3435302

CCCC(O)(c1nc2cc(Cl)c(Cl)cc2[nH]1)C(F)(F)F

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 5/20 0.71
GAA P10253 1/20 0.47
HTT P42858 1/20 0.47
PRKAG1 P54619 3/20 0.40
PRKAA2 P54646 3/20 0.40
PRKAB1 Q9Y478 3/20 0.40
CACNA1G O43497 2/20 0.39
CACNA1H O95180 1/20 0.39
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
PRCP P42785 2/20 0.38
PRKAA1 Q13131 1/20 0.38
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
LMNA P02545 1/20 0.37
GRIK1 P39086 1/20 0.37
GRIA1 P42261 1/20 0.37
GRIA2 P42262 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26799878 0.89 AR (0.74) ARGAAHTTPRKAG1PRKAA2
SCHEMBL12463531 0.85 AR (0.71) ARGAAHTTPRKAG1PRKAA2
SCHEMBL4789704 0.83 AR (0.63) ARGAAHTTPRKAG1PRKAA2
SCHEMBL5530939 0.82 AR (0.65) ARGAAHTTPRKAG1PRKAA2
SCHEMBL1635879 0.81 AR (0.79) ARGAAHTTPRKAG1PRKAA2
SCHEMBL24863637 0.81 AR (0.68) ARGAAHTTPRKAG1PRKAA2
SCHEMBL1635802 0.81 AR (0.73) ARGAAHTTPRKAG1PRKAA2
SCHEMBL1637447 0.80 AR (1.00) ARGAAHTTPRKAG1PRKAA2
SCHEMBL23378210 0.80 AR (1.00) ARGAAHTTPRKAG1PRKAA2
SCHEMBL1636632 0.80 AR (0.66) ARGAAHTTPRKAG1PRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100324095-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION SUMITOMO CHEMICAL COMPANY, LIMITED 2010-12-23 US disclosed
EP-2246334-A1 MEDICINAL COMPOSITION FOR INHIBITING AMYLOID- PROTEIN DEPOSITION Sumitomo Chemical Company, Limited (JP) 2010-11-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324095-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION APP, PSEN1, APBA1 AR 3720/4885GAA 173/4885HTT 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.